Regeneron’s FDA Success with Ebola Treating Antibody Cocktail, Inmazeb, Bodes Well for its COVID-19 Candidate
By Daniel Ojeda, Ph.D. On October 14th, 2020, Regeneron Pharmaceuticals, Inc., announced Inmazeb had become the first FDA-approved therapy to treat Zaire ebolavirus in adult and pediatric patients. Inmazeb showed …
Read More